Pharmaceuticals giant AstraZeneca has announced the acquisition of speciality pharmaceuticals company Omthera for a total cost of $443m (£293m) (release). The New Jersey based firm is focused on the development of therapies for abnormal levels of lipids in the blood.
Omthera's investigational product, Epanova, has been shown to reduce triglyceride levels and improve other key lipids parameters. The treatment is expected to be more convenient for patients.
Pascal Soriot, chief executive officer of AstraZeneca said:
The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes. There is a clear need for effective and convenient alternatives to some of the existing treatments.